The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure

Keyphrases

• Phosphodiesterase 100%
• Heart Failure Treatment 100%
• Phosphodiesterase Inhibitors 100%
• Cardiovascular System 66%
• Heart Failure 66%
• Contractility 33%
• Apoptosis 33%
• Cyclic GMP 33%
• Second Messenger 33%
• Cardiac muscle 33%
• Metabolic Pathway 33%
• Hypertrophy 33%
• Intracellular Metabolism 33%
• Fibrosis 33%
• Cyclic Adenosine Monophosphate (cAMP) 33%
• Phosphodiester Bond 33%
• As(III) 33%
• Cyclic nucleotides 33%
• Cyclic nucleotide Phosphodiesterase 33%
• Indirect Regulation 33%
• Adenosine 3′ 33%
• Selective Hydrolysis 33%
• Cyclic Function 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Congestive Heart Failure 100%
• Phosphodiesterase Inhibitor 100%
• Phosphodiesterase 75%
• Fibrosis 25%
• Lead Compound 25%
• Cyclic AMP 25%
• Cyclic Nucleotide Phosphodiesterase 25%
• Cyclic GMP 25%
• Cyclic Nucleotide 25%
• Phosphodiester Bond 25%